Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab

NCT01705977 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01705977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01705977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
November 27, 2012
Completion date
August 10, 2022
Enrollment
4,019 (actual)
Sites
250

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus